{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:36:41Z","timestamp":1774438601997,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult\u2010onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE\u2010PC), a pediatric\u2010aimed regimen designed to reduce late effects. We aimed to describe the single\u2010institution experience of using both regimens in patients with pediatric HL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study evaluated a total of 224 patients diagnosed with HL between 1999 and 2018 at Children's Hospital Los Angeles (CHLA), of which 93 patients were eligible having received ABVD (<jats:italic>n<\/jats:italic>\u00a0=\u00a046) or ABVE\u2010PC (<jats:italic>n<\/jats:italic>\u00a0=\u00a047) chemotherapy as their initial treatment. Descriptive analyses were performed using the Student's <jats:italic>t<\/jats:italic>\u2010test or Fisher's exact test. Survival analysis used the Kaplan\u2013Meier method. Events included death, relapse, and secondary malignancy. We also describe the use of radiation therapy, pulmonary toxicity, and cardiomyopathy determined by shortening fraction &lt;29%. Analyses followed an intention\u2010to\u2010treat principle.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no difference in baseline characteristics between the patients receiving ABVE\u2010PC or ABVD in regard for stage, risk group, or prognostic variables, such as the presence or absence of \u201cB\u201d symptoms, bulky disease, and extra\u2010nodal involvement. A greater proportion of patients treated with ABVE\u2010PC received consolidating external beam radiation treatment (XRT) either by randomization or by response compared to ABVD (59.6% vs. 32.6%, respectively, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.01). While not statistically significant, response to therapy, assessed by positron emission tomography\/computerized tomography (PET\/CT) where available, mirrored the use for radiation (rapid response 58.3% vs. 90.0%, <jats:italic>n<\/jats:italic>\u00a0=\u00a034, <jats:italic>p\u00a0<\/jats:italic>=\u00a0.11). The median dose of anthracycline (doxorubicin) was the same in patients receiving ABVE\u2010PC versus ABVD (200 vs. 200\u00a0mg\/m<jats:sup>2<\/jats:sup>, interquartile range 200\u2013250 vs. 200\u2013300\u00a0mg\/m<jats:sup>2<\/jats:sup>, <jats:italic>p\u00a0<\/jats:italic>=\u00a0.002). There was no difference in event\u2010free survival (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.63) or overall survival (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.37) with a median follow\u2010up length of 3.9\u00a0years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ABVD and ABVE\u2010PC achieved similar survival outcomes in our single\u2010institution cohort.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.29601","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T09:10:26Z","timestamp":1645434626000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE\u2010PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution"],"prefix":"10.1002","volume":"69","author":[{"given":"Sebastian","family":"de Armas","sequence":"first","affiliation":[{"name":"Loma Linda University School of Medicine  Loma Linda California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Huertas\u2010Ayala","sequence":"additional","affiliation":[{"name":"San Juan Bautista School of Medicine  Caguas Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-5164","authenticated-orcid":false,"given":"Randall Y.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Keck School of Medicine of the University of Southern California  Los Angeles California USA"},{"name":"Department of Pediatrics Los Angeles County+University of Southern California Medical Center  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueh\u2010Yun","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Keck School of Medicine of the University of Southern California  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-6622","authenticated-orcid":false,"given":"Winston W.","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Keck School of Medicine of the University of Southern California  Los Angeles California USA"},{"name":"Department of Pediatrics Children's Hospital Los Angeles  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Termuhlen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of Minnesota Medical School  Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-2862","authenticated-orcid":false,"given":"Paul S.","family":"Gaynon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Keck School of Medicine of the University of Southern California  Los Angeles California USA"},{"name":"Department of Pediatrics Children's Hospital Los Angeles  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra E.","family":"Kovach","sequence":"additional","affiliation":[{"name":"Department of Pathology Keck School of Medicine of the University of Southern California  Los Angeles California USA"},{"name":"Department of Pathology and Laboratory Medicine Children's Hospital Los Angeles  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8362-549X","authenticated-orcid":false,"given":"Andrew","family":"Doan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Keck School of Medicine of the University of Southern California  Los Angeles California USA"},{"name":"Department of Pediatrics Children's Hospital Los Angeles  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13372"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08975.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.1.27"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.9799"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.033"},{"key":"e_1_2_9_7_1","first-page":"263","article-title":"Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens","volume":"31","author":"Paoli D","year":"2016","journal-title":"Hum Reprod"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620711402414"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111961"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.5410"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184143"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30979"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007225"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001094"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001534"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2007.02.009"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/cci.18.00015"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6879"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2007.136093"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9381"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27375"},{"key":"e_1_2_9_23_1","unstructured":"National Comprehensive Cancer Network.Hodgkin Lymphoma (Version 1.2022).NCCN. Accessed January 11 2022.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29601","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T12:44:13Z","timestamp":1692967453000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/pbc.29601"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29601","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"2021-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29601"}}